idarubicin has been researched along with Thrombopenia in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (30.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, T; Xie, W; Yang, X; Ye, X; Zhao, S; Zhu, J; Zhu, L | 1 |
| Dailey, ME; Gorgan, MA; Mar, N; Vredenburgh, JJ | 1 |
| Brion, A; Chabin, M; Clavert, A; Colombat, P; Cumin, I; Delwail, V; Escoffre-Barbe, M; Gardembas, M; Ingrand, P; Lacotte-Thierry, L; Legouffe, E; Olivier, G; Solal-Celigny, P | 1 |
| Demir, M; Oztürk, E; Pamuk, GE; Taşçi, M | 1 |
| Go, RS; Johnston, KL | 1 |
| Dutcher, JP; Karbasian-Esfahani, M; Novik, Y; Paietta, E; Wiernik, PH | 1 |
| Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A | 1 |
| Bonadonna, G; Bonfante, V; Ferrari, L; Villani, F | 1 |
| Campbell, J; De La Serna, J; Diaz-Mediavilla, J; Francisco Tomás, J; García de Paredes, ML; Grande, C; Solano, C | 1 |
| Feliu, E; Hernández, JA; Millá, F; Navarro, JT; Oriol, A; Pujol, M; Ribera, JM; Sancho, JM | 1 |
| Kulkarni, S; Mainwaring, PN; Powles, RL; Raje, N; Ramiah, V; Sumpter, K; Treleaven, J | 1 |
| Anderson, A; Cameron, DA; Howell, A; Leonard, RC; Ostrowski, J | 1 |
| Barbarano, L; Bernuzzi, P; Gargantini, L; Morra, E; Nosari, A; Pungolino, E; Santoleri, L | 1 |
| Nilsson, B; Rödjer, S; Westin, J | 1 |
| Bastit, P; Chevallier, B; Hurteloup, P; Marty, M; Metz, R; Monnier, A; Namer, M; Roche, H | 1 |
| Howell, A; Smith, DB | 1 |
| Capnist, G; Chisesi, T; de Dominicis, E; Dini, E | 1 |
| Beer, M; Crespeigne, N; Dodion, P; Finet, C; Kenis, Y; Nicaise, C; Rozencweig, M | 1 |
| Di Lauro, L; Di Pietro, N; Ganzina, F; Lazzaro, B; Lopez, M; Papaldo, P | 1 |
| Kavanagh, JJ; Krakoff, IH; Savaraj, N; Yeung, KY | 1 |
1 review(s) available for idarubicin and Thrombopenia
| Article | Year |
|---|---|
Acute myelogenous leukemia in an adult with thrombocytopenia with absent radii syndrome.
Topics: Abnormalities, Multiple; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cytarabine; Cytokines; Female; Genetic Predisposition to Disease; Humans; Idarubicin; Leukemia, Myeloid, Acute; Menorrhagia; Neoplasm Proteins; Platelet Count; Proto-Oncogene Proteins; Radius; Receptors, Cytokine; Receptors, Thrombopoietin; Recurrence; Remission Induction; Risk; Syndrome; Thrombocytopenia | 2003 |
6 trial(s) available for idarubicin and Thrombopenia
| Article | Year |
|---|---|
A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Immunocompetence; Infections; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neutropenia; Palliative Care; Prednisolone; Recurrence; Remission Induction; Renal Insufficiency; Thrombocytopenia; Treatment Outcome; Vindesine | 2014 |
Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Thrombocytopenia | 2004 |
Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Agranulocytosis; Antibiotics, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Nausea; Remission Induction; Thrombocytopenia; Treatment Outcome; Vomiting | 1997 |
Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Humans; Idarubicin; Methylprednisolone; Middle Aged; Multiple Myeloma; Remission Induction; Salvage Therapy; Thrombocytopenia; Treatment Failure; Vincristine | 1999 |
Idarubicin and cyclophosphamide--an active oral chemotherapy regimen for advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Fatigue; Female; Humans; Idarubicin; Infections; Middle Aged; Thrombocytopenia | 2000 |
Do anthracyclines have a role in the therapy of multiple myeloma?
Topics: Aged; Aged, 80 and over; Agranulocytosis; Antibiotics, Antineoplastic; Disease Progression; Female; Humans; Idarubicin; Male; Middle Aged; Multiple Myeloma; Recurrence; Remission Induction; Salvage Therapy; Thrombocytopenia; Treatment Failure | 2000 |
13 other study(ies) available for idarubicin and Thrombopenia
| Article | Year |
|---|---|
Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy.
Topics: Adult; Anti-Bacterial Agents; Bone Marrow; Consolidation Chemotherapy; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Linezolid; Male; Middle Aged; Platelet Count; Retrospective Studies; Thrombocytopenia | 2020 |
Blue toes and a new pair of shoes--challenges in diagnosis and treatment of acute myelogenous leukemia.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Arterial Occlusive Diseases; Bone Marrow Examination; Combined Modality Therapy; Cyanosis; Cytarabine; Diagnosis, Differential; Disseminated Intravascular Coagulation; Fatal Outcome; Female; Humans; Idarubicin; Ischemia; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Shoes; Thrombectomy; Thrombocytopenia; Thrombosis; Toes; Ultrasonography | 2013 |
Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII : report on one case and review of other uses in acute leukemias.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Factor VIIa; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid, Acute; Recombinant Proteins; Remission Induction; Thrombocytopenia; Treatment Outcome | 2010 |
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Infections; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome | 2005 |
Phase I study of 4-demethoxydaunorubicin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Daunorubicin; Digestive System; Drug Evaluation; Female; Humans; Idarubicin; Injections, Intravenous; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia | 1983 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Hemorrhage; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Pancytopenia; Platelet Count; Platelet Transfusion; Retrospective Studies; Spain; Thrombocytopenia | 1998 |
Treatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Agranulocytosis; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Prednimustine; Thrombocytopenia; Treatment Outcome | 2000 |
Phase II study of oral idarubicin in elderly patients with advanced breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Breast Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Idarubicin; Neutropenia; Remission Induction; Survival Rate; Thrombocytopenia | 1990 |
A phase II trial of oral idarubicin plus dibromodulcitol in advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged; Mitolactol; Neutropenia; Thrombocytopenia | 1989 |
A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nausea; Thrombocytopenia | 1988 |
Phase I study of oral idarubicin given with a weekly schedule.
Topics: Administration, Oral; Adult; Aged; Daunorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Male; Middle Aged; Neoplasms; Risk; Thrombocytopenia | 1986 |
Phase II trial with oral idarubicin in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Middle Aged; Thrombocytopenia | 1986 |
Phase I clinical evaluation of oral and intravenous 4-demethoxydaunorubicin.
Topics: Administration, Oral; Adult; Aged; Agranulocytosis; Antineoplastic Agents; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Injections, Intravenous; Male; Middle Aged; Neoplasms; Thrombocytopenia | 1985 |